Incyte CEO sees $2B Vega deal aiding a post-Jakafi future

Bill Meury has been in or led the C-suite of several biopharma companies that have constructed multibillion-dollar exits over the past decade: Allergan, Karuna and Anthos. Now, he’s the one buying. In his first acquisition ...